Association between COX-2 gene expression and demographic clinical and pathologic characteristics
| . | . | COX-2 gene expression . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Variables . | n . | Median . | Range (min-max) . | P* . | ||||
| Sex | ||||||||
| Male | 19 | 1.44 | (0.39-7.20) | 0.10 | ||||
| Female | 21 | 3.28 | (0.04-7.73) | |||||
| Age, y | ||||||||
| <65 | 21 | 2.43 | (0.41-7.73) | 0.30 | ||||
| ≥65 | 19 | 1.80 | (0.04-5.86) | |||||
| Relapse category | ||||||||
| Liver metastasis | 19 | 2.03 | (0.52-5.65) | 0.54 | ||||
| Peritoneal and lymph node metastasis | 11 | 1.80 | (0.39-7.20) | |||||
| Lung metastasis | 6 | 3.38 | (0.39-5.86) | |||||
| Local recurrence | 4 | 5.18 | (0.04-7.73) | |||||
| Histology | ||||||||
| Well-differentiated adenocarcinoma | 30 | 2.29 | (0.39-7.73) | 0.89 | ||||
| Moderately differentiated adenocarcinoma | 7 | 1.80 | (0.04-7.20) | |||||
| Mucinous adenocarcinoma | 3 | 1.44 | (0.61-4.21) | |||||
| Performance status | ||||||||
| 0 | 3 | 5.40 | (0.04-5.65) | 0.82 | ||||
| 1 | 22 | 2.37 | (0.39-7.73) | |||||
| 2 | 15 | 1.80 | (0.41-7.20) | |||||
| Dose level | ||||||||
| 100 mg/d | 15 | 3.28 | (0.04-7.20) | 0.14 | ||||
| 120 mg/d | 25 | 1.80 | (0.39-7.73) | |||||
| . | . | COX-2 gene expression . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Variables . | n . | Median . | Range (min-max) . | P* . | ||||
| Sex | ||||||||
| Male | 19 | 1.44 | (0.39-7.20) | 0.10 | ||||
| Female | 21 | 3.28 | (0.04-7.73) | |||||
| Age, y | ||||||||
| <65 | 21 | 2.43 | (0.41-7.73) | 0.30 | ||||
| ≥65 | 19 | 1.80 | (0.04-5.86) | |||||
| Relapse category | ||||||||
| Liver metastasis | 19 | 2.03 | (0.52-5.65) | 0.54 | ||||
| Peritoneal and lymph node metastasis | 11 | 1.80 | (0.39-7.20) | |||||
| Lung metastasis | 6 | 3.38 | (0.39-5.86) | |||||
| Local recurrence | 4 | 5.18 | (0.04-7.73) | |||||
| Histology | ||||||||
| Well-differentiated adenocarcinoma | 30 | 2.29 | (0.39-7.73) | 0.89 | ||||
| Moderately differentiated adenocarcinoma | 7 | 1.80 | (0.04-7.20) | |||||
| Mucinous adenocarcinoma | 3 | 1.44 | (0.61-4.21) | |||||
| Performance status | ||||||||
| 0 | 3 | 5.40 | (0.04-5.65) | 0.82 | ||||
| 1 | 22 | 2.37 | (0.39-7.73) | |||||
| 2 | 15 | 1.80 | (0.41-7.20) | |||||
| Dose level | ||||||||
| 100 mg/d | 15 | 3.28 | (0.04-7.20) | 0.14 | ||||
| 120 mg/d | 25 | 1.80 | (0.39-7.73) | |||||
Based on the Wilcoxon or Kruskal-Wallis test.